Drug Resistant Epilepsy clinical trials

The registry lists 257 studies for Drug Resistant Epilepsy across more than 10 countries. 108 are recruiting or about to start. 212 of them are mainly about Drug Resistant Epilepsy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Drug Resistant Epilepsy studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 69
Recruiting: 66
Status unknown: 37
Not yet recruiting: 29
Terminated: 21
Active, not recruiting: 13

Phase

Phase 2: 39
Phase 3: 19
Phase 1: 14
Phase 4: 8
Early Phase 1: 8

Where

United States: 78
France: 35
China: 27
Italy: 21
United Kingdom: 20
Belgium: 17

Who runs them

Xuanwu Hospital, Beijing (14) · Beijing Pins Medical Co., Ltd (5) · Hospices Civils de Lyon (5) · Duke University (5) · University Hospital, Grenoble (4) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (4) · All India Institute of Medical Sciences, New Delhi (4) · Cedars-Sinai Medical Center (4)

What is being tested here

Drugs under test in Drug Resistant Epilepsy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cannabidiol	1	1	4
Opakalim	1	3	4
Cholecalciferol	1	1	2
Oral Aminolevulinic Acid Hydrochloride	1	0	1
Aminolevulinic Acid	1	0	1
Propranolol	1	0	1
Sirolimus	1	0	1
Padsevonil	0	1	3
Ketamine	0	1	2
Alpha-tocotrienol quinone	0	2	2

Coming up

5phase 3 studies under way

31studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy · Phase 3 · Biohaven Therapeutics Ltd.
Nov 2027Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials · Phase 3 · UMC Utrecht
Dec 2026Long-term Safety and Tolerability of BHV-7000 · Biohaven Therapeutics Ltd.
Dec 2026Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application · Dartmouth-Hitchcock Medical Center
Dec 2026A Multifaceted Assessment of Eating Behaviors, Anthropometric Measurements and Body Composition in Pediatric Patients With Drug-resistant Epilepsy on a Ketogenic Diet and Healthy Children · Wroclaw Medical University
Dec 2026Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic · Assistance Publique Hopitaux De Marseille
Dec 2026StereoEEG Motor Neuronal Potentials Decoding · Research Center of Neurology, Russia
Dec 2026Using Micro-filaments to Detect "fast Ripples" and Improve the Identification of the Epileptogenic Zone · Adrien Peyrache
Dec 2026A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy · NaviFUS Corporation
Jan 20275-SENSE Score Validation Study · Duke University

Who these studies take

Of the 66 Drug Resistant Epilepsy studies recruiting now, 26 (39%) set no upper age limit and 39 (59%) stop at 75 or younger. 25 (38%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 6 (9%) take healthy volunteers.

Recruiting studies that take each age, of 66
Age	Women	Men
10	20 (30%)	20 (30%)
18	61 (92%)	60 (91%)
30	56 (85%)	55 (83%)
40	55 (83%)	55 (83%)
50	54 (82%)	54 (82%)
65	44 (67%)	44 (67%)
75	32 (48%)	32 (48%)
85	26 (39%)	26 (39%)

Across all 257 studies, recruiting or not: 58% stop at 75 or younger and 50% at 65; 52% take children; 1% are for women only and <1% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Drug Resistant Epilepsy studies take

Of 102 interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Interventional, no phase	34 mo21–50 · 102 studies	—	40 mo21–… · 90 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Show 4 more

Characterisation of Laryngeal Evoked Potentials Induced by Vagus Nerve Stimulation in Refractory Epilepsy PatientsOct 29, 2026NCT07904039
Long-Term Epilepsy Outcomes in Children With a History of Perinatal StrokeOct 27, 2026NCT07898397
Prospective Longitudinal Study of Sleep, Brain Activity, and Plasma Analyses in Patients Undergoing Epilepsy SurgeryOct 21, 2026NCT07885826
Modified Ketogenic Diet on Drug-Resistant Epilepsy in Adults - a Prospective Observational Study of Real-world DataOct 16, 2026NCT07878104

Studies

Recruiting first, then most recently updated. Showing 50 of 257. Browse all 257 → or search them.